Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a biotechnology innovator focused on developing natural bioactive compounds derived from proprietary algal strains. This page serves as the definitive source for all official company announcements, research milestones, and strategic developments.
Investors and industry stakeholders will find timely updates including financial results, partnership agreements, regulatory filings, and scientific advancements. Our curated news feed provides essential insights into ZIVO's progress in nutraceutical research and biotech applications.
The page organizes content by key categories: quarterly earnings disclosures, product development breakthroughs, intellectual property updates, and corporate governance matters. Each news item is presented with clear context to help users assess material developments.
Bookmark this resource for streamlined tracking of Zivo Bioscience's advancements in algal-based biotechnology. Check regularly for verified updates directly from company filings and authorized communications.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) continues to focus on maximizing its product portfolio value derived from proprietary algal cultures. In a letter to shareholders, CEO John Payne highlights efforts in restructuring the company to drive revenue through two key initiatives: a biotech strategy targeting coccidiosis treatment in poultry and an agtech strategy aimed at commercial-scale production of nutritional products. The company aims to establish partnerships and scale manufacturing to enhance revenue generation, while ongoing studies may lead to product validation and regulatory approvals.
ZIVO Bioscience (NASDAQ: ZIVO) has received confirmation from the U.S. Department of Agriculture's Center for Veterinary Biologics of its jurisdiction over ZIVO's novel immune-modulating biologic for coccidiosis in broiler chickens. This parasitic disease affects poultry welfare and costs the industry over
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) has been added to the Russell Microcap® Index as of June 27, 2022, following the annual reconstitution. This membership will last for one year and enhances ZIVO's visibility among institutional investors, aiming to boost growth expectations. The Russell indexes, benchmarked by $12 trillion in assets, reflect market capitalization and style. CEO John Payne expressed optimism about increased investor interest and broadened stock exposure through this inclusion, which aligns with the company's ongoing strategy in biotech and agtech sectors.
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1), following a prior notice of noncompliance for not filing its Annual Report on Form 10-K for the year ended December 31, 2021. After filing the report on April 22, 2022, ZIVO received confirmation from Nasdaq on April 25, 2022, that it met the listing requirements again. The company focuses on R&D for therapeutic and nutritional products derived from algal cultures.
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) has appointed John B. Payne as President and CEO, succeeding Andrew A. Dahl. Payne, who has served on the Board since July 2013, expressed his enthusiasm for leading the company and emphasized the importance of its algae technology and management team. The Board highlighted Payne's extensive experience in the veterinary sector and his skills in managing growth businesses as vital for ZIVO's future. The company is focused on developing therapeutic and nutritional products from proprietary algal cultures.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced that CEO Andrew A. Dahl will present at the Global AgTech Virtual Conference on October 14, 2021, at 10 a.m. EDT. Dahl will speak during the Health and Wellness Panel. The conference features multiple panels with executives from the AgTech sector and a keynote speech by Ambassador Kip E. Tom, CEO of Tom Farms. Participants can attend the conference by signing up as M-Vest members. Zivo focuses on developing therapeutic products derived from proprietary algal cultures.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) has announced its annual shareholder meeting scheduled for October 12, 2021, at 9:00 a.m. EST. The meeting will be held virtually and in-person due to COVID-19 health concerns. Shareholders are directed to use their proxy card for Control IDs to participate, while the general public can use a standard Control ID of 000000000. Relevant proxy statements can be accessed via the provided links. Zivo specializes in developing therapeutic products derived from proprietary algal cultures for various health applications.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced significant progress in their financial and product development in a recent shareholder letter. The company successfully completed a capital raise of $12.2 million after its Nasdaq up-listing, enhancing its financial resources for R&D in biotech and agtech. Ongoing studies in poultry gut health and algal biomass applications are underway, indicating a commitment to innovation. They are also expanding operations in multiple locations, addressing COVID-related delays, and exploring new product potentials in health markets.
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech company, announced that CEO Andrew Dahl will present at two upcoming virtual investor conferences. He will speak at the Q3 Investor Summit on August 17, 2021, at 9:30 am ET, and at the SNN Network Summer Virtual Event on August 19, 2021, also at 9:30 am ET. Management will be available for one-on-one meetings during both events. Investors can register through the provided links. Zivo focuses on developing therapeutic and nutritional products from proprietary algal cultures for health benefits.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced the closing of the sale of an additional 150,000 shares of common stock at $4.99 per share, generating gross proceeds of approximately $748,500. This follows the partial exercise of the underwriters’ over-allotment option related to its public offering that closed on June 2, 2021. The offering was managed by Maxim Group LLC and Joseph Gunnar & Co., LLC. The shares were sold under the registration statements filed with the SEC. Zivo specializes in developing bioactive compounds derived from proprietary algal cultures for medicinal and nutritional applications.
